The authors undertook a patient-level meta-analysis to compare long-term outcomes after coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in 3,280 patients with left main or multivessel coronary artery disease (CAD).
. However, most of these trials are not large enough to resolve the uncertainties on optimal treatment for these diseases. Furthermore, limited data are available directly comparing the long-term outcomes of these 2 treatment strategies.
A meta-analysis of individual patient data from carefully conducted randomized trials may provide more useful information to guide the revascularization strategy than any individual study (15) . Such an analysis may have a greater power to assess the effects of a specific revascularization strategy on hard clinical outcomes and its separate effects among specific subgroups, providing robust evidence about the relative merits of CABG and contemporary PCI in these patient populations. Lee et al.
Strategies for Left Main or Multivessel Revascularization Previously reported definitions from each study are used for individual clinical outcomes (5) (6) (7) (8) (9) . Briefly, in the SYNTAX trial, myocardial infarction was defined as any myocardial infarction occurring after randomization, and its detailed definition was described elsewhere (5). In the BEST and PRECOMBAT trials Table 3 ). The median length of follow-up after randomization was 60 months (IQR: 48 to 61 months). Table 2 ). The difference was mainly The cumulative incidences of the primary outcome of death from any causes, myocardial infarction, or stroke (A), death from any causes (B), myocardial infarction (C), and stroke (D) are shown. The p values were calculated using the log-rank test with all available follow-up data. The percentages denote 5-year event rates.
CABG ¼ coronary artery bypass graft surgery; PCI ¼ percutaneous coronary intervention.
Lee et al. Table 2 ). Conversely, the need for repeat revascularization was significantly lower among patients who had undergone CABG than among those who had undergone PCI with DES (HR: 0.49; 95% CI: 0.40 to 0.59; p < 0.001) ( Table 2 ). In addition, we performed competing risk analysis, which showed consistent findings (Online Table 5 ). CI ¼ confidence interval; MI ¼ myocardial infarction; other abbreviations as in Table 1 . The cumulative incidences of the primary outcome of death from any causes, myocardial infarction, or stroke in patients with left main coronary artery disease (A), multivessel coronary artery disease (B), diabetes (C), and high SYNTAX scores ($33) (D) are shown. The p values were calculated using the log-rank test with all available follow-up data. The percentages denote 5-year event rates. CAD ¼ coronary artery disease; other abbreviations as in Figure 1 . 9 reduced the risk for all-cause death in subgroup of patients with multivessel CAD, demonstrating that CABG, as compared with PCI with DES, is the preferred method of revascularization for patients with severe CAD.
The rate of myocardial infarction was remarkably lower after CABG than after PCI with DES in subgroup of patients with multivessel CAD, supporting that CABG reduces the risk of myocardial infarction more effectively than does focal therapy of PCI with DES.
Recently, a large registry also showed that CABG versus PCI with newer-generation DES for the treatment of multivessel CAD was associated with a lower risk of myocardial infarction (19) . Acute coronary occlusion leading to myocardial infarction tends to cluster within the proximal third of each coronary artery (20, 21) , and the myocardium below the occlusion might be protected by bypass graft. DES treat the focal area of culprit lesions, whereas CABG might bypass the vulnerable area of each coronary artery that could lead to myocardial infarction over time (22) . In our study, however, there was no difference in all-cause death or myocardial infarction in subgroup of patients with left main CAD. This finding is in contrast to the result in those with multivessel CAD. The reasons for this difference remain Figure 1 .
Lee et al. showed similar efficacy and safety outcomes between 2 types of DES (26) (27) (28) (29) . In the present analysis, similar findings were observed among the 3 trials with no interaction between previous and newer-generation DES. In addition, irrespective of stent types, neoatherosclerosis inside the stent occurs over time (30, 31) . Considering that it is a major substrate for late DES failure, CABG seems to maintain its superiority over PCI even in the era of newer-generation DES.
Second, the present pooled analysis failed to include all randomized data including the FREEDOM trial, and it may have limited power to resolve small differences in mortality and stroke. In addition, the number of high-surgical-risk patients (EuroSCORE $6) was relatively small (18.2% of total patients), and our findings should be cautiously applied for these patients. Third, the definition of clinical outcomes was slightly different across trials. However, it will not influence the comparison between the 2 treatment strategies since they were randomized. Finally, antiplatelet agents and statins were less frequently used in the CABG group compared with the PCI group, which may be disadvantageous for the CABG group to protect against cardiovascular events. Nevertheless, CABG was better than PCI with DES in prevention of myocardial infarction. 
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